RBC Capital Remains On Sidelines For This MedTech Stock

  • Stryker Corporation SYK reported 1Q FY22 results that beat on the top and bottom line, reflecting a solid rebound in procedure volumes in March. 
  • SYK expects FY22 organic revenue growth in its 6-8% range. SYK called out the supply chain and inflation issues and expected EPS to come near the low-end of its $9.60-10.00 range. 
  • RBC Capital Market remains on the sidelines at this time and maintains a Sector Perform rating.
  • SYK reported Q1 sales of $4.3 billion, +8.1% Y/Y (+9.2% organic), exceeding consensus estimates and RBC estimate of $4.2 billion. 
  • The beat was broad-based, with numbers coming in above expectations for all sub-segments except for other ortho and neurovascular.
  • While the company did report a bounce back in surgical procedures and declining COVID-19 cases, supply chain challenges and electronic component shortages constrained sales growth. 
  • The impact was felt the most in SYK’s MedSurg business and Medical sub-segment.
  • SYK is also seeing inflation in freight costs hitting margins. SYK expects that Q2 should look similar to Q1 in terms of supply challenges. 
  • While the company does not expect a full recovery in the global supply chain before 2023, it does expect to be able to procure enough to meet demand by year-end.
  • Price Action: SYK shares are down 3.45% at $243.39 during the market session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorEarningsNewsHealth CareAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!